Friday, 15 Dec 2017

You are here

The RheumNow Week in Review – 21 April 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

  1. Long term followup of RA pts on Norfolk registry demonstrate better SURVIVAL when DMARDs are started early (<6 mos) https://t.co/Wy2OVFuw7l
  2. How Pfizer makes most of its $52.8 billion in 2016 - Surprisingly most from Prevnar 13 at $5.7 bill/year! https://t.co/bSy2GjLlj9
  3. Neutrophil to Lymphocyte ratio useful in assessing SLE w/ lympho/leukopenia from Rx or SLE? High (>2) w/ Dz activity https://t.co/NrbQaQ2xtA
  4. Acute Arthritis study shows ultrasound gout findings show sensitivity/specificity for 1) double contour 42/92%, 2) Intraarticular aggregates 58/92%, and 3) tophi 40/100.; all with a PPV 88-100% https://t.co/pf2T3JBAeU
  5. In animal models, high fat, high carbohydrate diet (junk food) promotes cartilage damage and osteoarthritis. https://t.co/70KgIrzh74
  6. Corrona study 1,567 PsA shows patients w/ dactylitis or enthesitis had more Dz activity, Pain, Fatigue, low work,HAQ https://t.co/2UcTOZKhYf
  7. Osteoarthritis Initiative 4367 pts shows 15% w/ recurrent falls, increased by 22-25% w/ opioid or antidepressant use https://t.co/LiIEANObvj
  8. Lyme disease hits 2016 record high in Maine; 1464 cases, up by 21% from 2015. Most increased Penobscot Co since 201… https://t.co/3LPj5wdisM
  9. Data from OP/OA mtg in Italy says Knee Osteoarthritis is associated wth a 13% higher risk of developing hypertension (P=.03) https://t.co/pEKJH0R7wj
  10. Norway population study shows self-reported dx of RA & AS highly inaccurate, 19% RA, 16% AS verified by hosp records https://t.co/zc2zIb1ZZY
  11. FDA Delays Baricitinib Decision
  12. The Cost of Not Taking Medicine
  13. Anti-IL-23 Therapy Effective in Crohn's Disease
  14. Paradoxical Toxicities with TNF Inhibitors
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

I am working in locum in Wisconsin and note that the EHR frequently lists a "problem" (not diagnosis) of Lyme disease. The majority of such patients have poorly documented disease manifestations with non-confirmatory serologies upon repeat or Western Blot. The majority are "diagnosed" and empirically treated in the ER or urgent care setting by a primary care doc based on non-specific complaints (when I started practice in 1978 such patients were labeled "chronic brucellosis", now they are labeled "chronic Lyme disease). Hence I am slow to accept any "reports" regarding the incidence of Lyme disease. More likely its the incidence of mis-dagnosis of Lyme disease. A + PPD does not equate to active TB (only exposure), and +serolgy for Lyme does not equate to active disease, only expoure to B. Bergdorfi.

More Like This

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations. 

RheumNow ACR 2017 Awards

The Annual Meeting of the American College of Rheumatology is a gargantuan educational and professional event that is on nearly everyone's radar each year. RheumNow had an expansive effort to cover this meeting and you can review the work of our faculty at ACR17.RheumNow.com.  But we have decided to take this one step further and today we are announcing our 2017 RheumNow ACR Awards.